Intravenous pamidronate versus oral and intravenous clodronate in bone metastatic breast cancer: a randomized, open-label, non-inferiority Phase III trial

PURPOSE: Patients with metastasized breast cancer often suffer from discomfort caused by metastatic bone disease. Thus, osteoprotection is an important part of therapy in breast cancer metastasized to bone, and bisphosphonates (BPs) are a major therapeutic option. In this study, our objectives were...

Descripción completa

Detalles Bibliográficos
Autores principales: von Au, Alexandra, Milloth, Eva, Diel, Ingo, Stefanovic, Stefan, Hennigs, Andre, Wallwiener, Markus, Heil, Joerg, Golatta, Michael, Rom, Joachim, Sohn, Christof, Schneeweiss, Andreas, Schuetz, Florian, Domschke, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944913/
https://www.ncbi.nlm.nih.gov/pubmed/27468239
http://dx.doi.org/10.2147/OTT.S103130

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944913/
https://www.ncbi.nlm.nih.gov/pubmed/27468239
http://dx.doi.org/10.2147/OTT.S103130

Ejemplares similares